Olympus Corporation
【Olympus】2026 Fiscal Year Financial Results｜Net Sales of ¥101.0 billion (+1.3%)｜Dividend ¥30｜Published on 2026-05-12
Olympus's consolidated financial results for the fiscal year ending March 2026 show net sales of ¥101.0 billion (up 1.3% YoY), operating profit of ¥9.7 billion (down 40.2%), with segment-wise growth driven by endoscopy but profit decline due to lower margins and investment expenses. The dividend remains at ¥30, continuing growth investments and shareholder returns this fiscal year.
Key Figures
- Net Sales: ¥101.0 billion (up 1.3% YoY)
- Operating Income: ¥9.7 billion (down 40.2% YoY)
- Net Income Attributable to Owners of the Parent: ¥6.8 billion (down 42.2% YoY)
AI要約
Performance Overview
For the fiscal year ending March 2026, consolidated net sales reached ¥101.0 billion (up 1.3% YoY), but operating income decreased significantly to ¥9.7 billion (down 40.2%). Segment-wise, growth in the endoscopy segment supported overall results, but net profit declined due to decreasing profit margins and investment burdens. The dividend remains at ¥30, with ongoing focus on growth investments and shareholder returns. The company is also actively promoting R&D and M&A activities.
Future Outlook and Impact on Shareholders
Next fiscal year's earnings forecast projects net sales of ¥105.5 billion to ¥106.0 billion, with a continued dividend of ¥30. The strategic focus is on steady growth in the endoscopy business and ongoing investments to improve profitability and competitiveness. While maintaining shareholder returns, Olympus aims for long-term growth through R&D and M&A. Financially, efforts will be made to enhance cash flow and capital efficiency, balancing stable dividends with shareholder value improvement.
Olympus Corporation
Company overview · Stock price · Financial data · All IR
